D.MihaiC
Telehealth programs now make it possible to access physician-guided care, personalized plans, and GLP-1 (semaglutide & tirzepatide) weight loss injections without in-office visits
, GLP-1 , ,
Headline results from ESSENCE, which formed the basis of that 2025 approval, included: About 63 percent of semaglutide-treated patients reached resolution of steatohepatitis without worsening of liver fibrosis at 72 weeks Approximately 37 percent showed measurable improvement in liver fibrosis (the scarring that drives long-term liver damage) Mean body-weight reduction reached roughly 10 percent over 72 weeks of weekly subcutaneous semaglutide Gastrointestinal symptoms (nausea, early fullness, mild diarrhea) were the most common side effects, generally manageable with gradual dose escalation Source: FDA Wegovy approval materials, 2025 (FDA Drugs) The SLIM LIVER Trial and What It Found in People with HIV The ESSENCE numbers above come from the general MASH population, not specifically from people living with HIV
Over decades of development in critical care medicine, effective early identification and therapeutic interventions, including early infection control, maintenance of hemodynamic stability and modulation of the host response, have successfully reduced mortality rates during the acute phase of sepsis, leading to an increase in the number of sepsis survivors (5-7)
How To Lower The Risk Of Hair Thinning And Protect Follicles Prioritize adequate daily protein
